PETROS G NIKOLINAKOS
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology ATHENS, GA NPI 1306041900
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology GA Gilead Sciences, Inc. All categories
General Payments — all program years on this page
$11,741.83
- Category: General Payments
- Program years: PY2018–2024
- Record count: 598
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $1,804.07 across 85 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,777.99 | 83 |
| Education | $26.08 | 2 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Gilead Sciences, Inc. | $200.53 | 10 |
| Merck Sharp & Dohme Corporation | $188.42 | 7 |
| Stemline Therapeutics Inc. | $154.99 | 6 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $150.05 | 6 |
| PFIZER INC. | $147.78 | 11 |
| GlaxoSmithKline, LLC. | $88.92 | 5 |
| Daiichi Sankyo Inc. | $87.91 | 4 |
| Janssen Biotech, Inc. | $86.45 | 4 |
| ABBVIE INC. | $84.57 | 4 |
| Exelixis Inc. | $76.19 | 3 |
| GENZYME CORPORATION | $74.10 | 4 |
| Regeneron Healthcare Solutions, Inc. | $66.61 | 2 |
| Mirati Therapeutics, Inc. | $64.07 | 3 |
| Bayer HealthCare Pharmaceuticals Inc. | $50.07 | 2 |
| ARRAY BIOPHARMA INC | $35.89 | 3 |
| Karyopharm Therapeutics Inc. | $33.76 | 1 |
| Celgene Corporation | $33.31 | 2 |
| Genmab U.S., Inc. | $32.40 | 1 |
| Tempus AI, Inc | $28.24 | 1 |
| Acerta Pharma LLC | $24.63 | 1 |
| E.R. Squibb & Sons, L.L.C. | $20.94 | 1 |
| AVEO Pharmaceuticals, Inc. | $20.00 | 1 |
| SERVIER PHARMACEUTICALS LLC | $18.73 | 1 |
| Ipsen Biopharmaceuticals, Inc | $18.00 | 1 |
| Sumitomo Pharma America, Inc. | $17.51 | 1 |
By program year
Records — PY2024 (85)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.